Our top pick for
China Pharma Holdings Inc is a drug manufacturers-specialty & generic business based in the US. China Pharma shares (CPHI) are listed on the NYSE MKT and all prices are listed in US Dollars. China Pharma employs 237 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.57|
|52-week range||$0.37 - $1.63|
|50-day moving average||$0.60|
|200-day moving average||$0.70|
|Wall St. target price||$3.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.09|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||4.02%|
|1 month (2021-09-21)||-3.03%|
|3 months (2021-07-21)||-20.54%|
|6 months (2021-04-21)||-20.54%|
|1 year (2020-10-21)||15.20%|
|2 years (2019-10-21)||120.12%|
|3 years (2018-10-19)||32.74%|
|5 years (2016-10-21)||169.35%|
Valuing China Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of China Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
China Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $48,255.
The EBITDA is a measure of a China Pharma's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$10.1 million|
|Gross profit TTM||$2 million|
|Return on assets TTM||-10.16%|
|Return on equity TTM||-51.08%|
|Market capitalisation||$24 million|
TTM: trailing 12 months
There are currently 204,951 China Pharma shares held short by investors – that's known as China Pharma's "short interest". This figure is 5.7% down from 217,385 last month.
There are a few different ways that this level of interest in shorting China Pharma shares can be evaluated.
China Pharma's "short interest ratio" (SIR) is the quantity of China Pharma shares currently shorted divided by the average quantity of China Pharma shares traded daily (recently around 280754.79452055). China Pharma's SIR currently stands at 0.73. In other words for every 100,000 China Pharma shares traded daily on the market, roughly 730 shares are currently held short.
However China Pharma's short interest can also be evaluated against the total number of China Pharma shares, or, against the total number of tradable China Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case China Pharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 China Pharma shares in existence, roughly 0 shares are currently held short) or 0.01% of the tradable shares (for every 100,000 tradable China Pharma shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against China Pharma.
Find out more about how you can short China Pharma stock.
We're not expecting China Pharma to pay a dividend over the next 12 months.
China Pharma's shares were split on a 1000:21804 basis on 14 August 2003. So if you had owned 21804 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your China Pharma shares – just the quantity. However, indirectly, the new 2080.4% higher share price could have impacted the market appetite for China Pharma shares which in turn could have impacted China Pharma's share price.
Over the last 12 months, China Pharma's shares have ranged in value from as little as $0.37 up to $1.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while China Pharma's is 0.2011. This would suggest that China Pharma's shares are less volatile than average (for this exchange).
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.